RRx-001 Given With Irinotecan and Temozolomide for Pediatric Patients With Recurrent or Progressive Malignant Solid and Central Nervous System Tumors

Clinical trial NCT04525014 · TERMINATED

Trial details

NCT number: NCT04525014
Sponsor: EpicentRx, Inc.
Status: TERMINATED
Phase: Phase 1
Study type: INTERVENTIONAL

Brain Tumor, Recurrent Brain Tumor, Pediatric Central Nervous System Neoplasms Unspecified Childhood Solid Tumor, Protocol Specific

Start date: 2023-01-26
Primary completion: 2024-07-29
Enrollment: 2

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.